Intensive management of obesity in people with Prader-Willi syndrome.
Obesity
Obesity pharmacotherapy
Prader-Willi syndrome
VLED
Weight loss
Journal
Endocrine
ISSN: 1559-0100
Titre abrégé: Endocrine
Pays: United States
ID NLM: 9434444
Informations de publication
Date de publication:
06 2022
06 2022
Historique:
received:
11
01
2022
accepted:
21
04
2022
pubmed:
8
5
2022
medline:
2
7
2022
entrez:
7
5
2022
Statut:
ppublish
Résumé
Prader-Willi syndrome (PWS) is characterised by childhood-onset hyperphagia and obesity however limited data are available to guide treatment of obesity in this population. We aimed to evaluate the safety, tolerability, and efficacy of intensive medical weight loss interventions (very-low-energy diets [VLED] and/or pharmacotherapy) in individuals with PWS attending a specialist obesity management service. A retrospective audit was undertaken of individuals with PWS attending the Austin Health Weight Control Clinic between January 2010-April 2021. Main outcome measures were weight outcomes, duration of use, and adverse effects. Data were available for 18 patients, of whom 15 were treated with intensive weight loss interventions. Median (interquartile range, IQR) age at baseline was 20 years (19-32) with median body weight 90 kg (75-118) and BMI 37 kg/m VLED and pharmacotherapy can achieve substantial weight loss in some individuals with PWS though non-adherence results in substantial weight regain. Adverse effects were ascribed to phentermine and topiramate, whereas liraglutide was well-tolerated in this population.
Identifiants
pubmed: 35524875
doi: 10.1007/s12020-022-03064-1
pii: 10.1007/s12020-022-03064-1
pmc: PMC9242929
doi:
Substances chimiques
Topiramate
0H73WJJ391
Liraglutide
839I73S42A
Phentermine
C045TQL4WP
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
57-62Informations de copyright
© 2022. The Author(s).
Références
M.G. Butler, A.M. Manzardo, J. Heinemann, C. Loker, J. Loker, Causes of death in Prader-Willi syndrome: Prader-Willi Syndrome Association (USA) 40-year mortality survey. Genetic Med. 19(6), 635–642 (2017). https://doi.org/10.1038/gim.2016.178
doi: 10.1038/gim.2016.178
T. Lionti, S.M. Reid, M.M. Rowell, Prader-Willi syndrome in Victoria: mortality and causes of death. J. Paediatr. Child Health 48(6), 506–511 (2012). https://doi.org/10.1111/j.1440-1754.2011.02225.x
doi: 10.1111/j.1440-1754.2011.02225.x
pubmed: 22697408
S.L. Einfeld, S.J. Kavanagh, A. Smith, E.J. Evans, B.J. Tonge, J. Taffe, Mortality in Prader-Willi syndrome. Am. J. Ment. Retard. 111(3), 193–198 (2006). https://doi.org/10.1352/0895-8017(2006)111[193:Mips]2.0.Co;2
doi: 10.1352/0895-8017(2006)111[193:Mips]2.0.Co;2
pubmed: 16597186
pmcid: 2422866
J.L. Miller, C.H. Lynn, J. Shuster, D.J. Driscoll, A reduced-energy intake, well-balanced diet improves weight control in children with Prader-Willi syndrome. J. Hum. Nutr. Diet. 26(1), 2–9 (2013). https://doi.org/10.1111/j.1365-277X.2012.01275.x
doi: 10.1111/j.1365-277X.2012.01275.x
pubmed: 23078343
M.D. Jensen, D.H. Ryan, C.M. Apovian, J.D. Ard, A.G. Comuzzie, K.A. Donato, F.B. Hu, V.S. Hubbard, J.M. Jakicic, R.F. Kushner, C.M. Loria, B.E. Millen, C.A. Nonas, F.X. Pi-Sunyer, J. Stevens, V.J. Stevens, T.A. Wadden, B.M. Wolfe, S.Z. Yanovski, H.S. Jordan, K.A. Kendall, L.J. Lux, R. Mentor-Marcel, L.C. Morgan, M.G. Trisolini, J. Wnek, J.L. Anderson, J.L. Halperin, N.M. Albert, B. Bozkurt, R.G. Brindis, L.H. Curtis, D. DeMets, J.S. Hochman, R.J. Kovacs, E.M. Ohman, S.J. Pressler, F.W. Sellke, W.K. Shen, S.C. Smith Jr., G.F. Tomaselli, 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation 129(25 Suppl 2), S102–S138 (2014). https://doi.org/10.1161/01.cir.0000437739.71477.ee
doi: 10.1161/01.cir.0000437739.71477.ee
pubmed: 24222017
P. Sumithran, L.A. Prendergast, C.J. Haywood, C.A. Houlihan, J. Proietto, Review of 3-year outcomes of a very-low-energy diet-based outpatient obesity treatment programme. Clin. Obes. 6(2), 101–107 (2016). https://doi.org/10.1111/cob.12135
doi: 10.1111/cob.12135
pubmed: 26841953
D. Fintini, G. Grugni, C. Brufani, S. Bocchini, M. Cappa, A. Crinò, Use of GLP-1 receptor agonists in Prader-Willi Syndrome: report of six cases. Diabetes Care 37(4), e76–e77 (2014). https://doi.org/10.2337/dc13-2575
doi: 10.2337/dc13-2575
pubmed: 24652737
N.B.H. Ng, Y.W. Low, D.D. Rajgor, J.M. Low, Y.Y. Lim, K.Y. Loke, Y.S. Lee, The effects of glucagon-like peptide (GLP)-1 receptor agonists on weight and glycaemic control in Prader-Willi syndrome: A systematic review. Clin. Endocrinol 96(2), 144–154 (2022). https://doi.org/10.1111/cen.14583
doi: 10.1111/cen.14583
S.L. Neoh, P. Sumithran, C.J. Haywood, C.A. Houlihan, F.T. Lee, J. Proietto, Combination phentermine and topiramate for weight maintenance: the first Australian experience. Med. J. Aust. 201(4), 224–226 (2014). https://doi.org/10.5694/mja13.00193
doi: 10.5694/mja13.00193
pubmed: 25164851
G. Felix, E. Kossoff, B. Barron, C. Krekel, E.G. Testa, A. Scheimann, The modified Atkins diet in children with Prader-Willi syndrome. Orphanet. J. Rare Dis. 15(1), 135 (2020). https://doi.org/10.1186/s13023-020-01412-w
doi: 10.1186/s13023-020-01412-w
pubmed: 32493369
pmcid: 7268481
K.A. Irizarry, D.R. Mager, L. Triador, M.J. Muehlbauer, A.M. Haqq, M. Freemark, Hormonal and metabolic effects of carbohydrate restriction in children with Prader-Willi syndrome. Clin. Endocrinol (Oxf) 90(4), 553–561 (2019). https://doi.org/10.1111/cen.13933
doi: 10.1111/cen.13933
L. Sze, L. Purtell, A. Jenkins, G. Loughnan, E. Smith, H. Herzog, A. Sainsbury, K. Steinbeck, L.V. Campbell, A. Viardot, Effects of a single dose of exenatide on appetite, gut hormones, and glucose homeostasis in adults with Prader-Willi syndrome. J. Clin. Endocrinol. Metab. 96(8), E1314–E1319 (2011). https://doi.org/10.1210/jc.2011-0038
doi: 10.1210/jc.2011-0038
pubmed: 21632815
M. Senda, S. Ogawa, K. Nako, M. Okamura, T. Sakamoto, S. Ito, The glucagon-like peptide-1 analog liraglutide suppresses ghrelin and controls diabetes in a patient with Prader-Willi syndrome. Endocrine 59(10), 889–894 (2012). https://doi.org/10.1507/endocrj.ej12-0074
doi: 10.1507/endocrj.ej12-0074
K. Cyganek, T. Koblik, E. Kozek, M. Wojcik, J. Starzyk, M.T. Malecki, Liraglutide therapy in Prader-Willi syndrome. Diabet Med. 28(6), 755–756 (2011). https://doi.org/10.1111/j.1464-5491.2011.03280.x
doi: 10.1111/j.1464-5491.2011.03280.x
pubmed: 21388446
Y.M. Kim, Y.J. Lee, S.Y. Kim, C.K. Cheon, H.H. Lim, Successful rapid weight reduction and the use of liraglutide for morbid obesity in adolescent Prader-Willi syndrome. Ann. Pediatr. Endocrinol Metab. 25(1), 52–56 (2020). https://doi.org/10.6065/apem.2020.25.1.52
doi: 10.6065/apem.2020.25.1.52
pubmed: 32252218
pmcid: 7136503
I.W. Seetho, G. Jones, G.A. Thomson, D.J. Fernando, Treating diabetes mellitus in Prader-Willi syndrome with Exenatide. Diabetes Res. Clin. Pract. 92(1), e1–e2 (2011). https://doi.org/10.1016/j.diabres.2010.12.009
doi: 10.1016/j.diabres.2010.12.009
pubmed: 21227526
R. Paisey, L. Bower, S. Rosindale, C. Lawrence, Successful treatment of obesity and diabetes with incretin analogue over four years in an adult with Prader–Willi syndrome. Practical Diabetes 28(7), 306–307 (2011). https://doi.org/10.1002/pdi.1621
doi: 10.1002/pdi.1621
P. Salehi, I. Hsu, C.G. Azen, S.D. Mittelman, M.E. Geffner, D. Jeandron, Effects of exenatide on weight and appetite in overweight adolescents and young adults with Prader-Willi syndrome. Pediatr. Obes. 12(3), 221–228 (2017). https://doi.org/10.1111/ijpo.12131
doi: 10.1111/ijpo.12131
pubmed: 27071367
A. Mottalib, S. Hafida, J. Mitri, MON-095 Phentermine Induces Weight Loss in Prader-Willi Syndrome. J. Endocr. Soc. 3 (S1) (2019). https://doi.org/10.1210/js.2019-MON-095
A. Consoli, S. Çabal Berthoumieu, M. Raffin, D. Thuilleaux, C. Poitou, M. Coupaye, G. Pinto, S. Lebbah, N. Zahr, M. Tauber, D. Cohen, O. Bonnot, Effect of topiramate on eating behaviours in Prader-Willi syndrome: TOPRADER double-blind randomised placebo-controlled study. Transl. Psychiatry 9(1), 274 (2019). https://doi.org/10.1038/s41398-019-0597-0
doi: 10.1038/s41398-019-0597-0
pubmed: 31685813
pmcid: 6828670
M.R. Puri, R. Sahl, S. Ogden, S. Malik, Prader-Willi syndrome, management of impulsivity, and hyperphagia in an adolescent. J. Child Adolesc. Psychopharmacol 26(4), 403–404 (2016). https://doi.org/10.1089/cap.2015.0240
doi: 10.1089/cap.2015.0240
pubmed: 27028699
Y.H. Choe, D.K. Jin, S.E. Kim, S.Y. Song, K.H. Paik, H.Y. Park, Y.J. Oh, A.H. Kim, J.S. Kim, C.W. Kim, S.H. Chu, E.K. Kwon, K.H. Lee, Hyperghrelinemia does not accelerate gastric emptying in Prader-Willi syndrome patients. J. Clin. Endocrinol. Metab. 90(6), 3367–3370 (2005). https://doi.org/10.1210/jc.2004-1651
doi: 10.1210/jc.2004-1651
pubmed: 15657368
T. Arenz, A. Schwarzer, T. Pfluger, S. Koletzko, H. Schmidt, Delayed gastric emptying in patients with Prader Willi Syndrome. J. Pediatr. Endocrinol. Metab. 23(9), 867–871 (2010). https://doi.org/10.1515/jpem.2010.140
doi: 10.1515/jpem.2010.140
pubmed: 21175084
D.A. Stevenson, J. Heinemann, M. Angulo, M.G. Butler, J. Loker, N. Rupe, P. Kendell, S.B. Cassidy, A. Scheimann, Gastric rupture and necrosis in Prader-Willi syndrome. J. Pediatr. Gastroenterol Nutr. 45(2), 272–274 (2007). https://doi.org/10.1097/MPG.0b013e31805b82b5
doi: 10.1097/MPG.0b013e31805b82b5
pubmed: 17667731
pmcid: 3241991
R.H. Wharton, T. Wang, F. Graeme-Cook, S. Briggs, R.E. Cole, Acute idiopathic gastric dilation with gastric necrosis in individuals with Prader-Willi syndrome. Am. J. Med. Genet. 73(4), 437–441 (1997). https://doi.org/10.1002/(sici)1096-8628(19971231)73:4<437::aid-ajmg12>3.0.co;2-s
doi: 10.1002/(sici)1096-8628(19971231)73:4<437::aid-ajmg12>3.0.co;2-s
pubmed: 9415471
J. Alexander, Y.H. Cheng, J. Choudhary, A. Dinesh, Phentermine (Duromine) precipitated psychosis. Aust. NZJ Psychiatry 45(8), 684–685 (2011). https://doi.org/10.3109/00048674.2011.580721
doi: 10.3109/00048674.2011.580721
M. Tauber, C. Hoybye, Endocrine disorders in Prader-Willi syndrome: a model to understand and treat hypothalamic dysfunction. Lancet Diabetes Endocrinol 9(4), 235–246 (2021). https://doi.org/10.1016/s2213-8587(21)00002-4
doi: 10.1016/s2213-8587(21)00002-4
pubmed: 33647242
clinicaltrials.gov: Effect of Liraglutide for Weight Management in Paediatric Subjects with Prader-Willi Syndrome (2021).
J.P.H. Wilding, R.L. Batterham, S. Calanna, M. Davies, L.F. Van Gaal, I. Lingvay, B.M. McGowan, J. Rosenstock, M.T.D. Tran, T.A. Wadden, S. Wharton, K. Yokote, N. Zeuthen, R.F. Kushner, Once-weekly semaglutide in adults with overweight or obesity. N. Engl. J. Med. 384(11), 989 (2021). https://doi.org/10.1056/NEJMoa2032183
doi: 10.1056/NEJMoa2032183
pubmed: 33567185